MAP2K1 and colorectal carcinoma: In addition, amplifications at EGFR, BRAF V600E, NRAS and KRAS loci, mutations of NRAS, KRAS and MAP2K1, and PTEN loss are often observed in resistant lesions of melanoma and CRC patients with treatment of combined RAF targeted therapies 85-87.